Evolus (EOLS) Operating Margin (2019 - 2026)
Evolus' (EOLS) quarterly Operating Margin came in at 9.36% in Q1 2026, up 1278.0% YoY from 0.68% in Q1 2025, and down 300.36% on a QoQ basis from 4.67% in Q4 2025.
Evolus (EOLS) Operating Margin (2019 - 2026) Analysis & Trends
Evolus (EOLS) has 8 years of Operating Margin data on file, last reported at 9.36% in Q1 2026.
- Quarterly Operating Margin rose 1278.0% year-over-year to 9.36% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.06% (up 670.0% YoY) and the FY2025 annual result came in at 10.99%, up 193.0% from the prior year.
- Operating Margin slipped to 9.36% in Q1 2026, from 4.67% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 4.67% in Q4 2025 to a low of 57.44% in Q2 2022.
- A 5-year average of 23.16% and a median of 22.14% in 2025 frame the typical range for Operating Margin.
- The widest YoY moves for Operating Margin: up 2765 bps in 2022, down 11113 bps in 2022.
- Tracing EOLS's Operating Margin over 5 years: stood at 24.37% in 2022, then surged by 42 bps to 14.16% in 2023, then jumped by 79 bps to 2.93% in 2024, then jumped by 259 bps to 4.67% in 2025, then sank by 300 bps to 9.36% in 2026.
- The last three Operating Margin figures came in at 9.36% (Q1 2026), 4.67% (Q4 2025), and 16.67% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.85 Bn | 39.19 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.40 Bn | 29.73 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.42 Bn | 15.03 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Evolus | 553.80 Mn | 508.63 Mn | 57.18 Mn | -5.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.40% |
| Mar 31, 2026 | -9.36% |
| Dec 31, 2025 | 4.67% |
| Sep 30, 2025 | -16.67% |
| Jun 30, 2025 | -14.71% |
| Mar 31, 2025 | -22.14% |
| Dec 31, 2024 | -2.93% |
| Sep 30, 2024 | -25.33% |
| Jun 30, 2024 | -11.51% |
| Mar 31, 2024 | -15.04% |
| Dec 31, 2023 | -14.16% |
| Sep 30, 2023 | -26.87% |
| Jun 30, 2023 | -30.64% |
| Mar 31, 2023 | -28.86% |
| Dec 31, 2022 | -24.37% |
| Sep 30, 2022 | -52.80% |
| Jun 30, 2022 | -57.44% |
| Mar 31, 2022 | -45.56% |
| Dec 31, 2021 | -52.02% |
| Sep 30, 2021 | -71.63% |